Table 1

The summary table for each working group (WG)

Working groups	Goals	Key issues to address	Expected deliverables
Planning and Drug Selection WG	To recommend a selection process and criteria for prioritising RWE evaluations	Potential markers or signals for emerging drugs. Policy issue around resource allocation and infrastructure for conducting RWE evaluations.	Criteria for selecting and prioritising RWE evaluation. Policy framework for drug selection for RWE evaluation. Prioritisation process for drug selection.
Data WG	To identify strategies for data access across provinces and harmonise data elements required for RWE studies	Determining data availability and accessibility of data on health or economic outcomes.	Recommendations on strategies to identify, access and harmonise the data elements required to undertake RWE projects in each province. Report on provincial data availability and accessibility for cancer specific RWE evaluation. Conduct RWE evaluations.
Methods WG	To recommend statistical methods to analyse real world data	Strengths and limitations of different analytical strategies. Appropriate methods for measuring and estimating key variables (safety, effectiveness and cost-effectiveness).	Recommendations on statistical methods to conduct RWE evaluations. Papers on conducting RWE evaluations.
Reassessment and Uptake WG	To make recommendation on a reassessment process and strategies for incorporating RWE results into policy decisions	How reassessment will be initiated and conducted. Funding decision revision.	Development of policy framework for reassessment and funding decision. Development of reassessment process. Recommendation on strategies for the uptake of the RWE framework.
Engagement WG	To ensure that all key stakeholders are given a voice in the development and implementation of the RWE framework	Engagement of patient groups, clinician groups, industry and payers.	Collect and provide feedback from patient groups, clinician groups, industry and payers.

RWE, real-world evidence.